An international study demonstrates that, administering niraparib after conventional chemotherapy treatment in patients newly diagnosed with advanced ovarian cancer, improves their progression-free survival, and reduces their risk of relapse or death from this disease. The primary investigator of this study is Dr. Antonio González Martín, (Co-Director of Clinica Universidad de Navarra (Spain), and president of the Spanish Ovarian Cancer Research Group (GEICO). The New England Journal of Medicine published the research online on September 28, 2019. The NEJM article is titled “Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.” "We evaluated in this study the benefits of using niraparib after standard treatment of ovarian cancer based on chemotherapy after surgery. With this new therapeutic approach, we have observed a significant improvement in patient progression-free survival and a reduction of almost 40% of their risk of relapse,”says Dr. González Martín, first author of the article. Ovarian cancer is diagnosed every year in approximately 205,000 women worldwide, and is the fifth leading cause of cancer death in women in Europe. It is usually diagnosed between 45 and 75 years, although there is a significant number of patients from 30 years. It is the gynecological tumor that causes more deaths because most patients are diagnosed in an advanced stage of the disease, given the absence of early diagnostic techniques. In turn, up to 80% of those affected by advanced ovarian cancer relapse after treatment with surgery and chemotherapy. "This research arises from the need to look for new strategies and alternative therapies that increase the survival of patients with this disease," says an expert.
Login Or Register To Read Full Story